156 related articles for article (PubMed ID: 36338747)
1. Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.
Zhang Y; Zhang L; Zhao Y; Wang S; Feng L
Front Oncol; 2022; 12():945867. PubMed ID: 36338747
[TBL] [Abstract][Full Text] [Related]
2. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Walter A; Rocconi RP; Monk BJ; Herzog TJ; Manning L; Bognar E; Wallraven G; Aaron P; Horvath S; Tang M; Stanbery L; Coleman RL; Nemunaitis J
Gynecol Oncol; 2021 Dec; 163(3):459-464. PubMed ID: 34702567
[TBL] [Abstract][Full Text] [Related]
3. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rocconi RP; Grosen EA; Ghamande SA; Chan JK; Barve MA; Oh J; Tewari D; Morris PC; Stevens EE; Bottsford-Miller JN; Tang M; Aaron P; Stanbery L; Horvath S; Wallraven G; Bognar E; Manning L; Nemunaitis J; Shanahan D; Slomovitz BM; Herzog TJ; Monk BJ; Coleman RL
Lancet Oncol; 2020 Dec; 21(12):1661-1672. PubMed ID: 33271095
[TBL] [Abstract][Full Text] [Related]
4. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Rocconi RP; Monk BJ; Walter A; Herzog TJ; Galanis E; Manning L; Bognar E; Wallraven G; Stanbery L; Aaron P; Senzer N; Coleman RL; Nemunaitis J
Gynecol Oncol; 2021 Jun; 161(3):676-680. PubMed ID: 33715892
[TBL] [Abstract][Full Text] [Related]
5. Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.
Barve M; Aaron P; Manning L; Bognar E; Wallraven G; Horvath S; Stanbery L; Nemunaitis J
Clin Med Insights Oncol; 2022; 16():11795549221110501. PubMed ID: 35957960
[TBL] [Abstract][Full Text] [Related]
6. ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
Rocconi RP; Stanbery L; Tang M; Walter A; Monk BJ; Herzog TJ; Coleman RL; Manning L; Wallraven G; Horvath S; Bognar E; Senzer N; Brun S; Nemunaitis J
Commun Med (Lond); 2022; 2():106. PubMed ID: 36051466
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.
Rocconi RP; Stanbery L; Madeira da Silva L; Barrington RA; Aaron P; Manning L; Horvath S; Wallraven G; Bognar E; Walter A; Nemunaitis J
Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452019
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Oh J; Barve M; Matthews CM; Koon EC; Heffernan TP; Fine B; Grosen E; Bergman MK; Fleming EL; DeMars LR; West L; Spitz DL; Goodman H; Hancock KC; Wallraven G; Kumar P; Bognar E; Manning L; Pappen BO; Adams N; Senzer N; Nemunaitis J
Gynecol Oncol; 2016 Dec; 143(3):504-510. PubMed ID: 27678295
[TBL] [Abstract][Full Text] [Related]
9. Comparison of survival and post-operation outcomes for minimally invasive versus open hepatectomy in hepatocellular carcinoma: A systematic review and meta-analysis of case-matched studies.
Fu B; Zhang JR; Han PS; Zhang YM
Front Oncol; 2022; 12():1021804. PubMed ID: 36338679
[TBL] [Abstract][Full Text] [Related]
10. Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients.
Xue C; Zheng S; Dong H; Lu X; Zhang X; Zhang J; Li J; Cui H
Front Oncol; 2021; 11():627016. PubMed ID: 34513654
[TBL] [Abstract][Full Text] [Related]
11. Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.
Sliheet E; Robinson M; Morand S; Choucair K; Willoughby D; Stanbery L; Aaron P; Bognar E; Nemunaitis J
Cancer Gene Ther; 2022 Jul; 29(7):993-1000. PubMed ID: 34785763
[TBL] [Abstract][Full Text] [Related]
12. The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Xu Y; Wang Q; Xie J; Chen M; Liu H; Zhan P; Lv T; Song Y
Front Oncol; 2021; 11():732214. PubMed ID: 34557415
[TBL] [Abstract][Full Text] [Related]
13. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
Front Oncol; 2022; 12():978069. PubMed ID: 36330494
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with
Ma J; Deng H; Li J; Hu S; Yang Y; Liu S; Han X
Cancer Manag Res; 2019; 11():3061-3078. PubMed ID: 31114351
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials.
Huang Q; Mei Z; Han X
Front Oncol; 2022; 12():972767. PubMed ID: 36119468
[TBL] [Abstract][Full Text] [Related]
16. Anti-Angiogenesis Maintenance Therapy in Newly Diagnosed and Relapsed Ovarian Cancer: A Meta-analysis of Phase III Randomized Controlled Trials.
Wang Y; Zhang S; Song Z; Ouyang L; Li Y
Front Pharmacol; 2021; 12():726278. PubMed ID: 34867330
[No Abstract] [Full Text] [Related]
17. Efficacy and Safety of Minimally Invasive Surgery Versus Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A Systematic Review and A Meta-Analysis.
Zeng S; Yu Y; Cui Y; Liu B; Jin X; Li Z; Liu L
Front Oncol; 2022; 12():900256. PubMed ID: 35924170
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
Guo C; Yan C; Qu L; Du R; Lin J
Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040
[TBL] [Abstract][Full Text] [Related]
19. Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
Rocconi RP; Stevens EE; Bottsford-Miller JN; Ghamande SA; Elder J; DeMars LL; Munkarah A; Aaron P; Stanbery L; Wallraven G; Bognar E; Manley M; Horvath S; Manning L; Walter A; Galanis E; Herzog T; Monk BJ; Coleman RL; Nemunaitis J
Cancer Gene Ther; 2022 Mar; 29(3-4):369-382. PubMed ID: 33753870
[TBL] [Abstract][Full Text] [Related]
20. Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: A meta-analysis with trial sequential analysis of randomized controlled trials.
Xie M; Zhong Y; Yang Y; Shen F; Nie Y
Front Oncol; 2022; 12():1039320. PubMed ID: 36387136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
